Login / Signup

Economic Cost and Sustainability of Oral Therapies in Precision Oncology.

Aakash P DesaiCaleb J ScheckelLeah C SoderbergChelsee Jo JensenJacob J OrmeSri H TellaAnuhya KommalapatiJoshua C PritchettNandita KheraAmit MahipalRonald S Gonull null
Published in: JCO oncology practice (2022)
The median CAGR in costs for modern oral precision-driven cancer therapeutic classes mostly outpaced CPI and the average inflation. Increase in cost within the same class should be weighed against incremental clinical benefit for the patients to ensure that rising costs do not limit access to targeted therapies.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • papillary thyroid
  • palliative care
  • squamous cell carcinoma
  • squamous cell
  • lymph node metastasis